Clinical trial for Heart Failure
Official title Cardiac Power Output in Cardiogenic Shock Patients
ClinicalTrials.gov ID: NCT05700617
What this study is testing
What is Milrinone?
an investigational drug being studied as a potential treatment for heart failure is designed to increase heart muscle contractility and cause blood vessel relaxation
Also referred to as Milrinone.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find out whether differences in the heart's reserve ability can predict clinical outcomes for these patients.
- Who it's for
- People with heart failure who are experiencing cardiogenic shock.
- What's involved
- Participants will have measurements of heart function, such as cardiac power output, taken during the study.
- Phase 1: an early, usually small safety study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- LVEF ≤ 40%
- Evaluation for advanced heart failure therapies, including LVAD, OHT, temporary or long-term inotrope therapy, or counter-pulsation (temporary or...
- Accurate assessment of invasive hemodynamics due to worsening clinical status, OR
- Assessment of myocardial recovery for consideration of LVAD or counter-pulsation (temporary IABP or long-term with NuPulse device) decommissioning or...
- Assessment of cardiac function and valvular abnormalities prior to planned valvular surgery for MR or AI
You likely can't join if
- eGFR \< 30 ml/min/1.73 m2
- Severe, non-revascularized coronary artery disease
- Concurrent acute coronary syndrome
- Age \< 18 years-old
- History of significant ventricular arrhythmia without an ICD
See the full eligibility criteria
- LVEF ≤ 40%
- Evaluation for advanced heart failure therapies, including LVAD, OHT, temporary or long-term inotrope therapy, or counter-pulsation (temporary or long-term with NuPulse device OR
- Accurate assessment of invasive hemodynamics due to worsening clinical status, OR
- Assessment of myocardial recovery for consideration of LVAD or counter-pulsation (temporary IABP or long-term with NuPulse device) decommissioning or removal OR
- Assessment of cardiac function and valvular abnormalities prior to planned valvular surgery for MR or AI
- Estimated glomerular filtration rate (eGFR) ≥ 30 ml/min/1.73 m2
- Age ≥ 18 years-old
- Intent for admission based on RHC data
- eGFR \< 30 ml/min/1.73 m2
- Severe, non-revascularized coronary artery disease
- Concurrent acute coronary syndrome
- Age \< 18 years-old
- History of significant ventricular arrhythmia without an ICD
The study team makes the final eligibility decision.
Where it is enrolling
- Chicago, Illinois, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Chicago, Illinois, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.